An engineered immunotherapy drug called 2141-V11 shrank tumors in half of patients with metastatic cancer when injected directly into a single tumor, with two achieving complete remission. Developed by Jeffrey V. Ravetch at Rockefeller University, the drug activates CD40 receptors on immune cells, triggering a body-wide anti-cancer response — even in tumors that were never injected.
Previous CD40 agonist antibodies showed promise in animal models but caused dangerous inflammation and liver toxicity when given intravenously. The breakthrough was twofold: Ravetch's team re-engineered the antibody to be 10 times more potent, and switched to direct tumor injection, which eliminated severe side effects. The drug creates tertiary lymphoid structures — immune cell clusters resembling lymph nodes — inside tumors, essentially turning them into immune training grounds.
Nearly 200 patients are now enrolled in expanded Phase 1/2 trials at Memorial Sloan Kettering and Duke University, testing the drug against bladder cancer, prostate cancer, and glioblastoma. Results from the initial 12-patient trial were published in Cancer Cell.
